ITEM 7.01 Regulation FD Disclosure.
On November 8, 2022, Bio-Rad Laboratories, Inc. (the "Company") provided an
update of its quarter-to-date repurchases under its share repurchase program
("Share Repurchase Program") that was authorized by the Company's Board of
Directors in November 2017, July 2020, and July 2022, granting the Company
authority to repurchase, on a discretionary basis, up to $650.0 million of
outstanding shares of our common stock. As of the previous quarter end on
September 30, 2022, $298.1 million of stock remained available under the Share
Repurchase Program.
Quarter-to-date, as of November 8, 2022, the Company has completed the purchase
of $67.1 million of the outstanding Class A shares of the Company's stock on the
open market pursuant to the Share Repurchase Program, leaving a remaining
authorization of $231.0 million. During this time period, the Company acquired
182,228 shares at an average purchase price of $368.40 per share, inclusive of
commissions. Repurchases under the Share Repurchase Program may be made at
management's discretion from time to time on the open market or through
privately negotiated transactions. The Share Repurchase Program has no time
limit and may be suspended for periods or discontinued at any time. Any shares
acquired will be available for general corporate purposes, including supporting
employee stock plans, funding acquisitions and minimizing dilution from stock
issuances. The Company may execute additional share repurchases at any time
until the full amount of the repurchase authorization is exhausted.
The information furnished pursuant to this Item 7.01 shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
BIO-RAD LABORATORIES, INC. 
